Andreas Herrmann

This inventor holds 11 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Beckman Research Institute, City of Hope, Sorrento Therapeutics, Inc.. Active years: 2020-2026.

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Pasadena, CA (US) (2020 - 2023)
Del Mar, CA (US) (2021 - 2024)
La Jolla, CA (US) (2024)

Company Filing History:

11 out of 692

Beckman Research Institute, City of Hope

patents

1 out of 114

Sorrento Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559479 - Cell penetrating cyanine-coupled antibodies (2026-02-24),

2. 11912995 - CTLA-4 aptamer conjugates (2024-02-27),

3. 11857633 - Phosphorothioate-conjugated miRNAs and methods of using the same (2024-01-02),

4. 11730789 - Cell penetrating antibodies (2023-08-22),

5. 11661463 - Cell penetrating protein-antibody conjugates and methods of use (2023-05-30),

6. 11607457 - Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same (2023-03-21),

7. 11541121 - Phosphorothioate-conjugated peptides and methods of using the same (2023-01-03),

8. 11186840 - CTLA-4 aptamer conjugates (2021-11-30),

9. 10987428 - Phosphorothioate-conjugated miRNAs and methods of using the same (2021-04-27),

10. 10967070 - Cell penetrating conjugates and methods of use thereof (2021-04-06),

11. 10711272 - CTLA-4 aptamer siRNA species (2020-07-14),

Title: Innovations and Contributions of Inventor Andreas Herrmann

Introduction

Andreas Herrmann is a prominent inventor based in Pasadena, CA, known for his significant contributions to the field of biotechnology. With a total of 10 patents to his name, Herrmann has made remarkable advancements in the development of nucleic acid compounds and their applications in medical treatments.

Latest Patents

One of Herrmann's latest patents is focused on CTLA-4 aptamer conjugates. This invention provides nucleic acid compounds that are useful for targeting CTLA-4-expressing cells and modulating their activity. The compositions can be incorporated into pharmaceutical formulations for the treatment of various conditions, including cancer, inflammatory diseases, infectious diseases, and metabolic diseases. Another notable patent involves phosphorothioate-conjugated miRNAs and methods of using them. This invention includes nucleic acid conjugates that enhance the stability and intracellular delivery of non-cell penetrating ribonucleic acid compounds. These conjugates are particularly useful for treating cancer, inflammatory diseases, and pain.

Career Highlights

Throughout his career, Herrmann has worked with esteemed organizations such as City of Hope and Sorrento Therapeutics, Inc. His work has significantly impacted the field of medical research and therapeutic development.

Collaborations

Herrmann has collaborated with notable colleagues, including Hua Yu and Marcin Tomasz Kortylewski, contributing to various innovative projects and research initiatives.

Conclusion

Andreas Herrmann's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence advancements in medical treatments and therapeutic applications.